Pinealon: A Literature Review of the Khavinson Bioregulator Program

Three amino acids. Glu, Asp, Arg. Pinealon is the smallest peptide in the Khavinson short-peptide-bioregulator catalog and one of the smallest molecules positioned as a transcription-factor-grade gene regulator anywhere in commercial peptide vending. The mechanism story its developers tell, that a three-residue peptide binds gene promoters in a sequence-specific manner and drives tissue-specific expression, runs against four decades of transcription-factor biochemistry.

Folded DNA-binding domains in evolved transcription factors run from twenty-five amino acids in zinc-finger units to five hundred and beyond in larger multi-domain proteins. A three-residue peptide of roughly four hundred and eighteen daltons lacks the residue count, the folding capacity, and the dimerization machinery that sequence-specific recognition of DNA requires.

That tension is the most interesting fact about Pinealon and the most underreported. Western coverage of the compound, vendor copy and affiliate review and Reddit thread and Wikipedia stub alike, frames the Khavinson framework as background context rather than as a claim to evaluate. The literature itself, almost entirely Russian-language and concentrated in a single laboratory's output, deserves a closer look.

Research content. The article below summarizes published preclinical, in vitro, and Russian-language observational research literature on Pinealon. The compound discussed is sold by Peerless Peptides for laboratory research use only and is not approved by the FDA for human or veterinary administration.

Last reviewed: May 20, 2026 by Peerless Research.

Summary

Pinealon is a synthetic three-amino-acid tripeptide, sequence Glu-Asp-Arg (single-letter EDR), developed at the Saint Petersburg Institute of Bioregulation and Gerontology within Vladimir Khavinson's short-peptide-bioregulator research program. Approximately twenty-two papers index under "Pinealon" in PubMed, with roughly eighty to ninety percent first or last author concentration in the Khavinson laboratory or in its institutional network. The compound is positioned in the Khavinson framework as a synthetic analog of an active fragment of bovine pineal-gland peptide extracts, although activity-guided fractionation from the parent extract is not documented in the public record^[1].

The preclinical evidence base spans in vitro cellular oxidative-stress assays, a Wistar-rat prenatal hyperhomocysteinemia model, an aged-rat hypoxia comparison series, and a small set of Russian-language elderly-cohort observational studies. The single non-Khavinson Western preclinical signal is a February 2026 bioRxiv preprint reporting a trend toward improved working memory in an eight-week multi-arm mouse screening assay. No high-resolution structural-biology demonstration of the Khavinson framework's central claim, that the EDR tripeptide binds DNA sequence-specifically, has been published.

Pinealon was not on the April 22, 2026 FDA 503A reclassification batch and is not on the July 23-24, 2026 Pharmacy Compounding Advisory Committee docket. Vladimir Khavinson died January 6, 2024.

Note: The research described below was conducted in in vitro cellular, rodent, and Russian-language observational cohort systems. Human safety and efficacy of Pinealon have not been established. This article is a literature review, not a recommendation of use.

The Smallest Bioregulator: Sequence, Chemistry, and Why EDR Is Not AEDG

Pinealon's primary structure is Glu-Asp-Arg, three free L-amino acids: L-glutamic acid, L-aspartic acid, L-arginine. Molecular formula C₁₅H₂₆N₆O₈ (verified by stoichiometric calculation: Glu C₅H₉NO₄ plus Asp C₄H₇NO₄ plus Arg C₆H₁₄N₄O₂ minus two water molecules from peptide-bond formation). Average molecular weight 418.41 grams per mole. CAS registry number 175175-23-2. PubChem Compound Identifier 10273502.

The peptide contains no aromatic residues (no tryptophan, tyrosine, or phenylalanine), so high-performance-liquid-chromatography purity is reported at 214 to 220 nanometers rather than at the more familiar 280-nanometer wavelength used for aromatic-bearing peptides. The N-terminal Glu and central Asp are acidic; the C-terminal Arg is basic. There is no cysteine for disulfide formation, no methionine for oxidation, and the Asp-Arg motif is not the canonical aspartimide hotspot (Asp-Gly is the high-risk sequence, present in Epitalon but not in Pinealon).

The most consequential chemistry fact about Pinealon, the one missing from most vendor descriptions and from the Wikipedia stub, is that Pinealon is not Epitalon. The two molecules are sister peptides from the same Khavinson Saint Petersburg laboratory, and the same provenance framework attributes both to the bovine pineal extract Epithalamin. The amino-acid compositional analysis of that extract identified peptide fragments at multiple lengths; synthetic short peptides matching the dominant stoichiometries were named as candidate active fragments.

The tripeptide EDR was named Pinealon. The tetrapeptide AEDG was named Epitalon. The two have distinct primary structures, distinct molecular formulas, and distinct chemistry.

Property	Pinealon	Epitalon
Sequence (one-letter)	EDR	AEDG
Sequence (three-letter)	Glu-Asp-Arg	Ala-Glu-Asp-Gly
Residue count	3	4
Molecular formula	C₁₅H₂₆N₆O₈	C₁₄H₂₂N₄O₉
Molecular weight (g/mol)	418.41	390.35
CAS registry	175175-23-2	307297-39-8
PubChem CID	10273502	219042
Originating laboratory	Khavinson IBG St. Petersburg	Khavinson IBG St. Petersburg
Russian regulatory status	Supplement (БАД)	Supplement (БАД)

Vendor copy occasionally attributes the AEDG tetrapeptide sequence to Pinealon, sometimes as "Pinealon (AEDG)" in a product description, sometimes by simply listing four amino acids in the chemistry block. Every primary chemistry source converges on EDR for Pinealon: the PubChem record at CID 10273502, the MedChemExpress catalog entry HY-P4052, the Khavinson 2011 Rejuvenation Research anchor paper, the Khavinson 2020 Molecules mechanism review, and the Silanteva 2019 Journal of Physical Chemistry B biophysics paper. AEDG belongs to Epitalon, and the conflation is consequential because it carries forward into mechanism reasoning that depends on which sequence is doing what.

Institutional Provenance: Khavinson IBG St. Petersburg, Not IMG Moscow

Pinealon was synthesized in Vladimir Khavinson's laboratory at the Saint Petersburg Institute of Bioregulation and Gerontology, part of the Russian Academy of Sciences. The lab's program, active from the 1970s onward, generated a catalog of roughly seventy organ-specific dipeptides, tripeptides, and tetrapeptides, each synthesized to match the amino-acid composition of a specific tissue extract.

Epithalamin (pineal) was the parent extract for Epitalon and Pinealon. Cortexin precursors (cortex) for Cortexin. Thymalin precursors (thymus) for Thymalin. Parallel lineages exist for Cardiogen, Vesugen, Vilon, Pancragen, Glandokort, and a longer list.

The distinction worth holding clearly is that the Khavinson Saint Petersburg program is not the same as the Institute of Molecular Genetics (IMG) program in Moscow. IMG Moscow produced Selank and Semax, two seven-amino-acid neuropeptides developed at the Myasoedov and Ashmarin laboratories using a different design template (a parent biological peptide plus a Pro-Gly-Pro stabilizer tail). The two programs share no molecules in common. The Khavinson catalog and the IMG Moscow catalog operate on different mechanism stories, in different cities, on different decades.

Grouping Pinealon with Selank or Semax under "Russian peptides" without qualification obscures that distinction, and inherits the methodological liabilities of the Khavinson framework in a place those liabilities do not belong. Pinealon is a Khavinson IBG Saint Petersburg molecule. Selank and Semax are IMG Moscow molecules.

The Khavinson narrative positions Pinealon as a synthetic analog of an "active fragment" of bovine pineal-gland peptide extracts. The parent preparation in this lineage is Epithalamin, a polydisperse pineal acid-acetone extract that has held Russian-Federation drug registration since the 1970s for menopause, infertility, and hormone-dependent tumor indications. The amino-acid composition analysis of Epithalamin identified free amino acids, dipeptides, tripeptides, tetrapeptides, and pentapeptides. Short synthetic peptides matching the dominant stoichiometries were synthesized and named as candidate active fragments. EDR became Pinealon; AEDG became Epitalon.

Activity-guided fractionation, the standard medicinal-chemistry workflow for isolating the active component of a heterogeneous extract by iterative bioassay-and-purification rounds, was not used. The inference that synthetic Pinealon recapitulates Epithalamin's biological activity rests on bulk-composition reasoning rather than on direct fractionation evidence. Direct mass-spectrometry detection of the EDR sequence in pineal-extract preparations is not prominent in the public record at the time of this review. "Pineal-derived peptide" framing in vendor copy is provenance-stretched: Pinealon is synthesized, not extracted, and the "active fragment" inference is not biochemically rigorous in the standard sense. This is the same provenance gap that exists for Epitalon, and the conflation between Russian-language clinical studies that tested Cerluten (the polydisperse pineal-extract consumer product) and studies that tested the synthetic tripeptide is a recurring source of error in Western secondary sources.

The Khavinson laboratory's founder, Vladimir Khavinson, died January 6, 2024 at age seventy-seven. The dominant author node across the entire Pinealon literature is permanently inactive. The post-Khavinson succession at IBG Saint Petersburg, and at the affiliated commercial vehicle NPCRIZ (Scientific-Production Center of Revitalization and Health, founded 2010 as the exclusive IBG licensee for the Cytogen consumer product line), has not been publicly clarified at the time of this review. NPCRIZ continues to distribute Pinealon under the Cytogen Pinealon brand as an oral capsule.

The Khavinson Framework: Why Three Amino Acids Cannot Bind DNA Sequence-Specifically

The central mechanistic claim of the Khavinson short-peptide-bioregulator program is that two-to-four-amino-acid peptides bind directly to gene promoters in a sequence-specific manner and drive tissue-specific gene-expression effects. For Pinealon specifically, the Khavinson 2020 Molecules review^[2] proposes that the EDR tripeptide enters cells, binds histone proteins and DNA, and modulates the promoter regions of PPARA, PPARG, SOD2, GPX1, and TPH1. Earlier work from the same group, the Fedoreyeva 2011 paper in Biochemistry (Moscow)^[3], reports fluorescence-quenching evidence that EDR binds preferentially to deoxyribooligonucleotides containing the CNG sequence motif, where N stands for any base and CNG sites are the canonical targets for cytosine DNA methylation in eukaryotes.

Standard transcription-factor biochemistry, accumulated across four decades of structural-biology work on yeast, fly, mouse, and human proteins, sets out specific requirements for sequence-specific recognition of DNA major-groove contacts. Folded DNA-binding domains in evolved transcription factors require structured scaffolding to position the recognition residues correctly relative to the DNA double helix.

Zinc-finger domains span twenty-three to twenty-eight amino acids per finger and typically appear in arrays of three to eleven fingers, totalling one hundred to three hundred residues. Basic helix-loop-helix domains span fifty to eighty amino acids. Homeodomains are roughly sixty-residue three-helix bundles.

Leucine zippers function as dimerized coiled-coils. Most transcription-factor binding sites are palindromic or pseudo-palindromic, and recognition by the canonical machinery requires dimer or higher-order oligomer geometry, not monomer binding.

A three-amino-acid peptide of approximately four hundred and eighteen daltons lacks the residue count for major-groove sequence-specific recognition. It lacks the folding capacity for stable secondary structure. It lacks the dimerization interface that almost every characterized transcription factor uses. It lacks the metal-coordination motifs that zinc fingers depend on. The Khavinson framework's claim is not that EDR mimics a known transcription factor; it is that EDR functions as a novel category of gene-expression regulator using a mechanism that has not been demonstrated for any peptide of comparable size in any other published research program.

The evidence base offered in support of the framework consists of three classes of experiment. Fluorescence-quenching assays use fluorescent-labeled peptides and ethidium-bromide-stained oligonucleotides to measure peptide-DNA proximity; this reports physical interaction but does not, by the criteria of standard structural biology, establish sequence-specific binding-affinity-grade evidence. In-silico molecular docking generates computational predictions of peptide-promoter interaction at named genomic sites; predictions of this kind require orthogonal experimental confirmation. Cellular gene-expression readouts after peptide exposure measure endpoints that are downstream of any number of plausible mechanisms, only some of which involve direct DNA binding.

No high-resolution co-crystal structures of an EDR-DNA complex have been deposited in the Protein Data Bank. No isothermal titration calorimetry measurements of EDR-DNA affinity have been published. No surface plasmon resonance kinetics. No nuclear-magnetic-resonance titration with chemical-shift mapping of either peptide or DNA. The orthogonal biophysical confirmation that the Khavinson framework requires, fifteen years after the founding 2011 Rejuvenation Research paper, has not appeared.

The single peptide-DNA biophysics paper from an institutional address outside the Khavinson IBG network is Silanteva et al. 2019 in the Journal of Physical Chemistry B^[4], from Saint Petersburg State University. The paper examines EDR-DNA interactions in the presence of mono- and divalent ions and confirms physical interaction at the same fluorescence-quenching grade as the earlier Khavinson work. Sequence-specific recognition under modern structural-biology criteria is not demonstrated. The institutional reach extends within the Saint Petersburg metropolitan research community; it does not reach the Western structural-biology consortia whose verification would matter for the framework's broader acceptance.

The framework is not falsified by absence of evidence, and that is worth saying plainly. Absence of structural-biology demonstration is not proof that the framework is wrong. It is, however, an unusually long replication gap on a foundational mechanistic claim, in a research program with substantial commercial output, and that gap is the single most important fact about how to read the rest of the Pinealon literature.

Preclinical Evidence: In Vitro Oxidative Stress and Rat Prenatal Models

The anchor in-vitro paper for Pinealon is Khavinson et al. 2011, published in Rejuvenation Research^[5]. The study examined EDR in three cell systems at the IBG Saint Petersburg laboratory: cerebellar granule cells, neutrophils, and PC12 rat pheochromocytoma cells, under oxidative challenge by hydrogen peroxide. The reported readouts included dose-dependent reactive-oxygen-species accumulation reduction, decreased necrotic cell death by propidium-iodide assay under H₂O₂ exposure, delayed ERK1/2 activation kinetics, and cell-cycle modulation that continued at peptide concentrations above the ROS-suppression saturation point.

The work is methodologically conventional for early-2010s in-vitro biology. The reported observations sit within the range of effects reported for other short peptides bearing charged residues in oxidatively stressed cellular systems. Related Khavinson-group in-vitro work has reported similar patterns: lipid-peroxidation restriction in cerebellar tissue comparable to other short peptides in the Khavinson catalog including Vesugen, Vilon, and Epitalon (Kozina et al. 2008^[6]), modified signaling-molecule expression in organotypic pineal-cell culture, and altered TPH1-pathway involvement with reported serotonin-expression effects in cortical neurons (Khavinson et al. 2014^[7]). The specific cellular signatures, reactive-oxygen-species suppression in oxidatively challenged systems, are observed across many short peptides containing acidic and basic residues; whether the effects are specific to the EDR sequence rather than to general charged-short-peptide biology has not been disentangled in head-to-head preparations outside the Khavinson program.

The anchor in-vivo paper is Arutjunyan et al. 2012, published in the International Journal of Clinical and Experimental Medicine^[8]. The preparation used Wistar rats: pregnant females weighing 180 to 200 grams received methionine loading in drinking water from the second trimester onward, and Pinealon was administered intraperitoneally for five days prior to methionine loading. Family-level sample size was six per arm, with approximately eight to nine pups per brood. Offspring readouts included Morris water-maze spatial-learning measures, cerebellar reactive-oxygen-species concentrations, and necrotic cell fraction under H₂O₂ challenge in cerebellar tissue. The reported result was offspring spatial-learning recovery toward control levels in the EDR-administered arm and reduced cerebellar oxidative-stress markers compared with the methionine-loaded control arm.

Two methodological caveats matter for reading the Arutjunyan result. The family-level sample size of six is small; pup-level analysis can inflate effective n if litter clustering is not modelled, and the published methods at journal-house standard do not address this in modern multi-level-model detail. The Khavinson laboratory remains the sole institutional address for the experimental data. The result is consistent with general reactive-oxygen-species suppression mechanisms attributable to charged short peptides in oxidatively stressed maternal-fetal models; it does not require the sequence-specific gene-expression mechanism that the Khavinson framework invokes.

Preclinical Evidence: Aged-Rat Hypoxia and the First Non-Khavinson Western Signal

A series of papers from the Mendzheritsky and Karantysh group at Rostov-na-Donu has compared Pinealon to Cortexin in aged-rat models of hypoxia, hypothermia, and carotid-occlusion stress, with caspase-3 protein expression and behavioral endpoints as readouts^[9]. The institutional address is non-IBG, but the research culture sits within the broader Khavinson-affiliated network, and the publication venue (Advances in Gerontology) is the in-house Khavinson-program journal. The reported pattern across the series is that Cortexin shows more pronounced effect on certain endpoints and Pinealon contributes on others. The papers are mostly Russian-language. Sample sizes are small; designs are non-blinded; comparator selection and dose decisions reflect the convention of the Khavinson research culture rather than the modern preregistered-protocol standard.

The single non-Khavinson Western preclinical signal in the indexed Pinealon literature is a February 2026 bioRxiv preprint by Marín-Jerez and colleagues at the Aubrai decentralized-science consortium: "Short-Term Performance Assay Identifies Functional Benefits and Early Toxicity of Longevity Interventions in Mice," deposited under the digital object identifier 10.64898/2026.02.25.707674v1. The study used an eight-week multi-arm screening assay in mice and tested five longevity-candidate interventions: 17α-estradiol, the combination of rapamycin plus Smer28, the combination of berberine plus resveratrol, sildenafil, and Pinealon. Endpoints included body weight and temperature, food intake, grip strength, locomotor activity, Y-maze cognition, social behavior, hematology, and urinalysis.

The reported Pinealon-arm observation was a trend toward improved working memory with no detectable adverse effects. The 17α-estradiol comparator arm induced significant weight loss, increased grip strength, and dorsal alopecia consistent with metabolic remodeling.

Two facts about the preprint are worth holding clearly. It is the first independent preclinical signal for Pinealon outside the Khavinson IBG network in fifteen years from the 2011 Rejuvenation Research anchor paper, and it is the first comprehensive preclinical aging study fully funded through tokenized decentralized-science (DeSci) infrastructure. The signal itself is modest: a trend rather than a statistically definitive primary endpoint, a small effective n in a multi-arm screening design rather than a powered single-intervention format, and a preprint that has not yet been peer-reviewed at the time of this review.

The funding-source novelty does not change the evidence grade, but it does change the institutional picture of who is asking the question. For fifteen years, no Western laboratory funded by NIH or by a pharmaceutical sponsor has run a controlled preclinical experiment on Pinealon. The first one is community-funded. That is itself a fact about how Pinealon has sat outside the conventional research-funding stream, and it is the most important development in the molecule's Western literature since the 2011 anchor paper.

Clinical Evidence: Russian-Language Observational Cohorts

A query of ClinicalTrials.gov for Pinealon, EDR peptide, or Glu-Asp-Arg returns zero registered NCT records as of May 2026. The European Union Clinical Trials Register and other major non-Russian national trial registries return zero records. No randomized controlled trial of synthetic Pinealon under modern preregistration standards has been published.

The Russian-language clinical record consists of observational studies in the journal Advances in Gerontology, all from researchers within the Khavinson-affiliated research network. Bashkireva and Artamonova 2012^[10] co-administered Pinealon and Vesugen to a cohort of professional truck drivers with reported neurotic disorders; the authors describe the joint administration as showing "optimal results" relative to comparator conditions. Nazimko 2012 examined locomotive-brigade workers, measuring biological-age parameters and reported adaptation indices, and concluded "positive use of the peptide bioregulator Pinealon in maintenance of the professional reliability." Meshchaninov et al. 2015^[11] applied multiple peptide bioregulators to elderly patients with chronic polymorbidity and reported organic-brain-syndrome characteristics in remission, with comparative analysis indicating Vesugen produced "more visible geroprophylactic effect than Pinealon." Myakotnykh 2016 conducted a broader comparative analysis of multiple bioregulators in aging cohorts.

The methodological gaps common to this Russian-cohort literature limit how much weight the studies can carry under modern epidemiological criteria. The designs are non-randomized and frequently non-blinded. Sample sizes are inadequate for the effect sizes claimed. Healthy-adherer and selection bias are not addressed in the published analyses.

Co-administration with multiple bioregulators makes single-compound attribution impossible across most of the cohort papers. Publication concentration in a single Khavinson-affiliated journal limits the diversity of editorial review. Endpoints (cognitive batteries, occupational-reliability indices, "biological age" composite scores) vary across papers without standardized definitions. And in some cases, the test article was Cerluten (the polydisperse pineal-extract consumer product) rather than synthetic Pinealon, the same conflation that affects the broader Khavinson literature.

Modern geroscience meta-analyses, including those that draw on the standard short-lived-controls and modern-statistical-criteria filters, routinely exclude the Khavinson/Anisimov rodent lifespan literature on those grounds; the Russian elderly-cohort literature on Pinealon faces an analogous exclusion under standard epidemiological criteria. The cohorts as published do not support causal inference about Pinealon's effects in humans.

Research Limitations: Four Load-Bearing Critiques

The Pinealon evidence base differs from most other research peptides in the indexed primary literature by the structure of its methodological gaps. Four critiques sit at the load-bearing level, and the rest of the limitations follow from them.

First, the central mechanism, sequence-specific binding of a three-amino-acid peptide to gene-promoter DNA, runs against four decades of transcription-factor biochemistry. Folded DNA-binding domains require structured scaffolding, dimerization machinery, and metal-coordination motifs that a three-residue peptide cannot supply. The framework's evidence base consists of fluorescence-quenching, in-silico docking, and cellular gene-expression readouts; no high-resolution structural-biology confirmation has been published in any venue, by any laboratory, in the fifteen years since the founding 2011 anchor paper.

Second, the citation concentration in the Khavinson IBG Saint Petersburg research network is at the upper end of the indexed research-peptide literature, comparable to Epitalon, with roughly eighty to ninety percent of indexed Pinealon papers carrying first or last author Khavinson-group affiliation. The non-IBG exceptions (Silanteva 2019 from Saint Petersburg State University; the Mendzheritsky/Karantysh group at Rostov-na-Donu) operate within the broader Russian Khavinson-affiliated research culture. Independent replication by laboratories outside that orbit is essentially absent until the 2026 bioRxiv preprint.

Third, the Russian regulatory status of synthetic Pinealon is supplement-tier, not registered drug. Within the Khavinson catalog, Cortexin, Thymalin, and the parent pineal extract Epithalamin hold Russian Federation drug registration; Pinealon and Epitalon do not. The Russian-approved credibility halo that legitimately applies to Semax and Selank (IMG Moscow registered drugs) does not transfer to Pinealon. Statements characterizing Pinealon as a Russian-approved drug are not supported by the regulatory record.

Fourth, Vladimir Khavinson died January 6, 2024. The dominant author node across the literature is permanently inactive. Linkova, Trofimova, Ryzhak, and other senior IBG investigators remain active, but the post-Khavinson institutional succession is publicly unclear. The fifteen-year replication gap from the 2011 anchor paper widens further in a post-Khavinson environment, and the first non-Khavinson Western preclinical signal, the 2026 bioRxiv preprint, is a single screening assay funded outside the conventional research-grant system, not peer-reviewed at the time of this writing.

None of these critiques is a falsification of the Khavinson framework. Each is a description of the evidence's current grade and reach. Readers comparing Pinealon to better-characterized research peptides should weight the literature accordingly, and should regard assertions about Pinealon's cellular mechanism, animal-model effects, and human applications with appropriate hedging by the criteria of contemporary structural biology, modern preclinical methodology, and standard epidemiological analysis.

Regulatory Context: Unmarked, Not Approved

The U.S. Food and Drug Administration has not evaluated Pinealon for any indication. Pinealon has never been registered as an investigational new drug, has never appeared on the FDA's 503A Category 2 bulk-drug-substance do-not-compound list, and is not on the positive 503A Category 1 list. On April 22, 2026, the FDA reclassified twelve peptides that had been on the 503A Category 2 list, removing them from the do-not-compound designation: the listed peptides were BPC-157, LL-37, DiHexa, DSIP, Epitalon, GHK-Cu injectable, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500. Pinealon was not among them; Pinealon was never on the Category 2 list to begin with.

The Pharmacy Compounding Advisory Committee meeting scheduled for July 23 and 24, 2026 reviews several peptides on the Category 2 list. Day One covers BPC-157, KPV, TB-500, and MOTS-c. Day Two covers DSIP, Semax, and Epitalon. Pinealon is on neither day's agenda. The molecule's regulatory posture is therefore neither marked-and-deferred (as with Epitalon and the peptides scheduled for PCAC review) nor permitted (as with substances on the Category 1 positive list). Pinealon's posture is unmarked-but-unapproved. Both postures, marked-and-deferred and unmarked-but-unapproved, sit on the same legal ground under the Federal Food, Drug, and Cosmetic Act: unapproved new drug, lawful only for research-use-only research-chemical sale to qualified researchers.

The World Anti-Doping Agency Prohibited List for 2026 does not name Pinealon explicitly. The molecule is captured by Section S0 (Non-Approved Substances), the catch-all clause for substances without current marketing authorization by any governmental regulatory health authority.

In Russia, synthetic Pinealon is registered as a biologically active food supplement (БАД, the Russian regulatory category for dietary supplements) and is sold by NPCRIZ under the Cytogen consumer-product line as an oral capsule. It does not hold Russian Federation drug registration. The Russian regulatory record matches the synthetic Pinealon supplement-tier status to that of Epitalon and distinguishes both from the registered-drug status of Cortexin, Thymalin, and the parent pineal-extract Epithalamin.

No 2024 to 2026 FDA warning letter has specifically named Pinealon in its enforcement description. The molecule has not been the subject of public criminal indictment, civil enforcement, or U.S. Customs and Border Protection seizure announcement in the public record review for this article. Whether Pinealon will be nominated for future PCAC review under the post-April-2026 framework, and whether NPCRIZ or successor entities will pursue Russian Minzdrav drug registration for the synthetic tripeptide, are open questions at the time of this writing.

References

1. Khavinson VKh. Peptides and ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12624841.

2. Khavinson V, Linkova N, Kozhevnikova E, Trofimova S. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules. 2020;26(1):159. PMID: 33396470. DOI: 10.3390/molecules26010159.

3. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011;76(11):1210-1219. PMID: 22117547.

4. Silanteva IA, Komolkin AV, Morozova EA, Vorontsov-Velyaminov PN, Kasyanenko NA. Role of Mono- and Divalent Ions in Peptide Glu-Asp-Arg-DNA Interaction. J Phys Chem B. 2019;123(8):1786-1795. PMID: 30762356.

5. Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res. 2011;14(5):535-541. PMID: 21978084.

6. Kozina LS, Arutiunian AV, Stvolinskiĭ SL, Khavinson VKh. Biological activity of regulatory peptides in model experiments in vitro. Adv Gerontol. 2008;21(1):68-73. PMID: 18546826.

7. Khavinson VKh, Lin'kova NS, Tarnovskaya SI, Umnov RS, Elashkina EV, Durnova AO. Short peptides stimulate serotonin expression in cells of brain cortex. Bull Exp Biol Med. 2014;157(1):77-80. PMID: 24909721.

8. Arutjunyan A, Kozina L, Stvolinskiy S, Bulygina Y, Mashkina A, Khavinson V. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med. 2012;5(2):179-185. PMID: 22567179.

9. Mendzheritskiĭ AM, Karantysh GV, Ryzhak GA, Dem'ianenko SV. Regulation of content of cytokines in blood serum and of caspase-3 activity in brains of old rats in model of sharp hypoxic hypoxia with Cortexin and Pinealon. Adv Gerontol. 2014;27(1):94-97. PMID: 25051764.

10. Bashkireva AS, Artamonova VG. The peptide correction of neurotic disorders among professional truck-drivers. Adv Gerontol. 2012;25(4):717-724. PMID: 23734521.

11. Meshchaninov VN, Tkachenko EL, Zhuravlev VF, Katyreva YE, Gavrilov IV. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Adv Gerontol. 2015;28(2):332-339. PMID: 26390612.

12. Marín-Jerez E, Rueda-Carrasco J, Meléndez-Rodríguez F, Partido-Borge P, Tapia E, Leibowitz BD, Parras A. Short-Term Performance Assay Identifies Functional Benefits and Early Toxicity of Longevity Interventions in Mice. bioRxiv preprint, deposited February 26, 2026. DOI: 10.64898/2026.02.25.707674v1. Not peer-reviewed at the time of this writing.

Not intended to diagnose, treat, cure, mitigate, or prevent any disease. Sold for research, laboratory, or analytical purposes only.